Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
OUTBACK re‐entry catheter vs manual re‐entry months' primary patency rate · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Ungraded |
OUTBACK re‐entry catheter vs manual re‐entry Limb salvage · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Ungraded |
OUTBACK re‐entry catheter vs manual re‐entry Complications · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy Clinical improvement: ABI improvement Significant postexercise ABI improvement · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.86 [0.68, 1.08] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy Technical success rate · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.97 [0.88, 1.07] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy months' patency rate · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.75 [0.57, 1] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy months' patency rate · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.74 [0.55, 1] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy months' patency rate · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.76 [0.52, 1.11] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy months' limb salvage rate · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.97 [0.9, 1.05] | 1 study · 95 participants | Low |
Subintimal angioplasty with stenting vs remote endarterectomy Complications · 95 people with Rutherford 3 to 5 TASC‐II D lesions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | RR 0.77 [0.14, 4.42] | 1 study · 95 participants | Low |
OUTBACK re‐entry catheter vs manual re‐entry Clinical improvement · 52 people with TASC‐II D superficial femoral artery chronic total occlusions Subintimal angioplasty for lower limb arterial chronic total occlusions (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Ungraded |
Endovenous laser ablation vs conventional surgery Recanalisation or persistence of reflux at 6 weeks · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | OR 0.07 [0.02, 0.22] | 3 studies · 289 participants | Moderate |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Clinical evidence of recurrence after 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Reintervention (due to technical failure) · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Disease‐specific QoL (AVVQ) at 6 weeks · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 33 participants | Ungraded |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Disease‐specific QoL (AVVQ) at 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Complications at 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Endovenous laser ablation vs conventional surgery Recurrence of reflux at 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | OR 0.24 [0.07, 0.77] | 2 studies · 119 participants | Low |
Endovenous laser ablation vs conventional surgery Clinical evidence of recurrence after 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | OR 0.54 [0.17, 1.75] | 1 study · 99 participants | Low |
Endovenous laser ablation vs conventional surgery Reintervention (due to technical failure) · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 99 participants | Moderate |
Endovenous laser ablation vs conventional surgery Disease‐specific QoL (AVVQ) at 6 weeks · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 2 studies · 265 participants | Moderate |
Endovenous laser ablation vs conventional surgery Disease‐specific QoL (AVVQ) at 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 1 study · 99 participants | Low |
Endovenous laser ablation vs conventional surgery Complications at 6 weeks · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | no estimate extracted | 2 studies · 265 participants | Moderate |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Recanalisation or persistence of reflux at 6 weeks · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | OR 0.34 [0.06, 2.1] | 1 study · 33 participants | Low |
Ultrasound‐guided foam sclerotherapy vs conventional surgery Recurrence of reflux at 1 year · people requiring intervention for short saphenous vein varices Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical… (2016) · Cochrane | OR 1.19 [0.29, 4.92] | 1 study · 31 participants | Low |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Amputation · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | OR 1.56 [0.73, 3.33] | 9 studies · 1649 participants | High |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Primary vessel patency · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | OR 1.92 [1.45, 2.56] | 3 studies · 882 participants | High |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Target lesion revascularization · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | OR 0.4 [0.31, 0.51] | 11 studies · 1900 participants | Low |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Binary restenosis · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | OR 0.38 [0.15, 0.98] | 4 studies · 1094 participants | Moderate |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Death · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | OR 1.09 [0.64, 1.85] | 9 studies · 1649 participants | High |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Change in Rutherford category · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | no estimate extracted | 3 studies · 623 participants | Moderate |
Drug‐eluting balloon vs uncoated balloon angioplasty at 12 months Change in ankle‐brachial index · people with peripheral arterial disease of the lower limbs Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the… (2016) · Cochrane | no estimate extracted | 3 studies · 656 participants | High |
Intervention NR Incidence of recurrent VTE · patients with venous thromboembolism Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (2014) · Cochrane | RR 0.2 [0.11, 0.38] | 10 studies · 3536 participants | High |
Intervention NR Incidence of major bleeding · patients with venous thromboembolism Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (2014) · Cochrane | RR 3.44 [1.22, 9.74] | 6 studies · 1350 participants | Moderate |
Intervention NR Mortality · patients with venous thromboembolism Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism (2014) · Cochrane | RR 0.69 [0.35, 1.34] | 4 studies · 1049 participants | Moderate |
Intervention NR Days of catheter patency · Children with central venous catheter Heparin‐bonded catheters for prolonging the patency of central venous catheters in children (2014) · Cochrane | no estimate extracted | 1 study · 200 participants | Low |
Intervention NR Catheter‐related thrombosis at any time during catheter stay · Children with central venous catheter Heparin‐bonded catheters for prolonging the patency of central venous catheters in children (2014) · Cochrane | RR 0.34 [0.01, 7.68] | 2 studies · 287 participants | Moderate |
Intervention NR Occlusion of catheter within one week of catheter insertion · Children with central venous catheter Heparin‐bonded catheters for prolonging the patency of central venous catheters in children (2014) · Cochrane | RR 0.06 [0, 1.07] | 1 study · 200 participants | Low |
Intervention NR Catheter‐related blood stream infection and CVC‐related colonization · Children with central venous catheter Heparin‐bonded catheters for prolonging the patency of central venous catheters in children (2014) · Cochrane | RR 0.06 [0.01, 0.41] | 1 study · 200 participants | Low |
Intervention NR Side effects: Thrombocytopenia after catheter insertion · Children with central venous catheter Heparin‐bonded catheters for prolonging the patency of central venous catheters in children (2014) · Cochrane | RR 0.73 [0.38, 1.39] | 2 studies · 287 participants | Low |
Statin vs placebo All cases of VTE · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | OR 0.57 [0.37, 0.86] | 1 study · 17802 participants | Moderate |
Statin vs placebo Pulmonary embolism · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | no estimate extracted | 1 study · 17802 participants | Moderate |
Statin vs placebo Deep vein thrombosis · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | no estimate extracted | 1 study · 17802 participants | Moderate |
Statin vs placebo Any MI · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | OR 0.45 [0.3, 0.69] | 1 study · 17802 participants | Moderate |
Statin vs placebo Any stroke · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | OR 0.51 [0.34, 0.78] | 1 study · 17802 participants | Moderate |
Statin vs placebo Death · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | OR 0.8 [0.66, 0.96] | 1 study · 17802 participants | Moderate |
Statin vs placebo Any serious adverse event · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL) Statins for primary prevention of venous thromboembolism (2014) · Cochrane | OR 1.07 [0.95, 1.2] | 1 study · 17802 participants | Moderate |
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Fixed‐effect analysis) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | OR 1.55 [0.78, 3.07] | 3 studies · 496 participants | Very low |
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Random‐effects analysis) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | OR 1.32 [0.43, 4.06] | 3 studies · 496 participants | Very low |
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Risk Difference) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | no estimate extracted | 3 studies · 496 participants | Very low |